ReViral gets a $55M booster shot of cash as it expands its development work on an RSV treatment
Six months after ReViral outlined the efficacy of their respiratory syncytial virus, or RSV, treatment in healthy adults with an intranasal infection, the London-based biotech has raised a $55 million B round to take the next big step in the clinic.
ReViral got started with seed money for their discovery work from the Wellcome Trust in 2012 and then moved toward the clinic with a $21 million launch round in 2015. Now they’re blueprinting a Phase IIb trial to test an RSV fusion inhibitor dubbed RV521 that is designed to block viral replication as a way to protect an at-risk population.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
